|
【结 构 式】 
|
【分子编号】50802 【品名】(3S,4R,5S)-4-[(tert-butoxycarbonyl)amino]-3-[[tert-butyl(dimethyl)silyl]oxy]-5-methylheptanoic acid 【CA登记号】 |
【 分 子 式 】C19H39NO5Si 【 分 子 量 】389.6079 【元素组成】C 58.57% H 10.09% N 3.6% O 20.53% Si 7.21% |
合成路线1
该中间体在本合成路线中的序号：(IV)Coupling of benzyloxy isovalery propionic acid (Bzl-Hip-OH) (I) with leucine trimethylsilylethyl ester (II) by means of HOBt and DCC followed by hydrogenation over Pd/C in isopropanol for benzyl protecting group removal provides dipeptide (III), which is then converted into compound (V) by first coupling to Boc-Sta(TBDMS)-OH (IV) by means of DMAP and DCC followed by removal of the TMSe group by means of TBAF. Coupling between Z-D-N-MeLeu-OH (VI) and H-Thr-OTMSe (VII) by means of N-hydroxysuccinimide (NHS) and EDC yields protected dipeptide (VIII), which is then condensed with dipeptide (IX) by means of DMAP and DCC and then treated with HCl in EtOAc for Boc removal to afford tetrapeptide (X) (in turn, dipeptide (IX) can be obtained by coupling between Boc-Pro-OH (XI) and Me2Tyr-ONb (XII) by means of EDC followed by p-nitrobenzyl removal by hydrogenation over Pd/C in HOAc). Coupling of tetrapeptide (X) with compound (V) by means of EDC, HOBt leads to formation of linear peptide (XIII), which is partially deprotected by treatment with TBAF and TFA and then cyclized by means of HOBt, EDC and NMM, providing macrolide (XIV).
| 【1】 Rinehart, K.L.; et al.; Total synthesis of didemnins A, B, and C. J Am Chem Soc 1987, 109, 22, 6846. |
| 中间体序号 | 中间体编号 | 品名 | CAS号 | 分子式 | 供应商 | 用于合成 |
|---|---|---|---|---|---|---|
| (I) | 50799 | (2S,4S)-4-(benzyloxy)-2,5-dimethyl-3-oxohexanoic acid | C15H20O4 | 详情 | 详情 | |
| (II) | 50800 | 2-(trimethylsilyl)ethyl (2S)-2-amino-4-methylpentanoate | C11H25NO2Si | 详情 | 详情 | |
| (III) | 50801 | 2-(trimethylsilyl)ethyl (2S)-2-[[(2S,4S)-4-hydroxy-2,5-dimethyl-3-oxohexanoyl]amino]-4-methylpentanoate | C19H37NO5Si | 详情 | 详情 | |
| (IV) | 50802 | (3S,4R,5S)-4-[(tert-butoxycarbonyl)amino]-3-[[tert-butyl(dimethyl)silyl]oxy]-5-methylheptanoic acid | C19H39NO5Si | 详情 | 详情 | |
| (V) | 50803 | (6R,7S,11S,13S,16S)-7-[[tert-butyl(dimethyl)silyl]oxy]-16-isobutyl-11-isopropyl-2,2,13-trimethyl-6-[(1S)-1-methylpropyl]-4,9,12,14-tetraoxo-3,10-dioxa-5,15-diazaheptadecan-17-oic acid | C33H62N2O9Si | 详情 | 详情 | |
| (VI) | 50772 | (2R)-2-[[(benzyloxy)carbonyl](methyl)amino]-4-methylpentanoic acid | C15H21NO4 | 详情 | 详情 | |
| (VII) | 50804 | 2-(trimethylsilyl)ethyl (2S,3R)-2-amino-3-hydroxybutanoate | C9H21NO3Si | 详情 | 详情 | |
| (VIII) | 50805 | 2-(trimethylsilyl)ethyl (2S,3R)-2-([(2R)-2-[[(benzyloxy)carbonyl](methyl)amino]-4-methylpentanoyl]amino)-3-hydroxybutanoate | C24H40N2O6Si | 详情 | 详情 | |
| (IX) | 50806 | (2S)-2-[[[(2S)-1-(tert-butoxycarbonyl)pyrrolidinyl]carbonyl](methyl)amino]-3-(4-methoxyphenyl)propionic acid | C21H30N2O6 | 详情 | 详情 | |
| (X) | 50807 | 2-(trimethylsilyl)ethyl (2S,3R)-2-([(2R)-2-[[(benzyloxy)carbonyl](methyl)amino]-4-methylpentanoyl]amino)-3-[((2S)-3-(4-methoxyphenyl)-2-[methyl[(2S)pyrrolidinylcarbonyl]amino]propanoyl)oxy]butanoate | C40H60N4O9Si | 详情 | 详情 | |
| (XI) | 16734 | (2S)-1-(tert-butoxycarbonyl)tetrahydro-1H-pyrrole-2-carboxylic acid; N-alpha-t-BOC-L-proline; (2S)-1-(tert-butoxycarbonyl)-2-pyrrolidinecarboxylic acid | C10H17NO4 | 详情 | 详情 | |
| (XII) | 50808 | C11H14NNbO3 | 详情 | 详情 | ||
| (XIII) | 50809 | 2-(trimethylsilyl)ethyl (2S,3R)-2-([(2R)-2-[[(benzyloxy)carbonyl](methyl)amino]-4-methylpentanoyl]amino)-3-[[(2S)-2-[[((2S)-1-[(2S,5S,7S,11S,12R)-11-[[tert-butyl(dimethyl)silyl]oxy]-2-isobutyl-7-isopropyl-5,16,16-trimethyl-12-[(1S)-1-methylpropyl]-4 | C73H120N6O17Si2 | 详情 | 详情 | |
| (XIV) | 50810 | benzyl (1R)-1-[([(3S,6R,7S,10R,11S,15S,17S,20S,25aS)-11-hydroxy-20-isobutyl-15-isopropyl-3-(4-methoxybenzyl)-2,6,17-trimethyl-10-[(1S)-1-methylpropyl]-1,4,8,13,16,18,21-heptaoxodocosahydro-15H-pyrrolo[2,1-f][1,15,4,7,10,20]dioxatetraazacyclotricosin | C57H84N6O14 | 详情 | 详情 |
合成路线2
该中间体在本合成路线中的序号：(XI)Activation of N-Boc-D-allo-isoleucine (VII) with carbonyl diimidazole, followed by condensation with the lithium enolate of methyl acetate provided keto ester (VIII). Keto group reduction in (VIII) by means of KBH4 led to the isostatine derivative (IX), which was further hydrolyzed to acid (X) with NaOH in aqueous dioxane. Silylation of hydroxy acid (X) at both the alcohol and carboxyl groups employing tert-butyldimethylsilyl chloride and imidazole, followed by selective desilylation of the carboxyl group with NaOH afforded the protected amino hydroxy acid (XI)
| 【1】 Jou, G.; Gonzalez, I.; Albericio, F.; Lloyd-Williams, P.; Giralt, E.; Total synthesis of dehydrodidemnin B. Use of uronium and phosphonium salt coupling reagents in peptide synthesis in solution. J Org Chem 1997, 62, 2, 354. |
| 【2】 Giralt Lledo, E.; Albericio Palomera, F.; Lloyd-Williams, P.; Gonzalez Valcarcel, I.; Jou Prat, G.; Gomez Gonzalez, A.; Manzanares Secades, I. (PharmaMar, SA); Process for the preparation of didemnine A. ES 2102322 . |
| 中间体序号 | 中间体编号 | 品名 | CAS号 | 分子式 | 供应商 | 用于合成 |
|---|---|---|---|---|---|---|
| (VII) | 50775 | (2R,3S)-2-[(tert-butoxycarbonyl)amino]-3-methylpentanoic acid | C11H21NO4 | 详情 | 详情 | |
| (VIII) | 62533 | methyl (4R,5S)-4-[(tert-butoxycarbonyl)amino]-5-methyl-3-oxoheptanoate | C14H25NO5 | 详情 | 详情 | |
| (IX) | 62534 | methyl (3S,4R,5S)-4-[(tert-butoxycarbonyl)amino]-3-hydroxy-5-methylheptanoate | C14H27NO5 | 详情 | 详情 | |
| (X) | 52722 | (3S,4R,5S)-4-[(tert-butoxycarbonyl)amino]-3-hydroxy-5-methylheptanoic acid | C13H25NO5 | 详情 | 详情 | |
| (XI) | 50802 | (3S,4R,5S)-4-[(tert-butoxycarbonyl)amino]-3-[[tert-butyl(dimethyl)silyl]oxy]-5-methylheptanoic acid | C19H39NO5Si | 详情 | 详情 |
合成路线3
该中间体在本合成路线中的序号：(XI)A modification of the previous synthetic methods was further reported. The protected isostatine (XI) was prepared by a related procedure utilizing benzyl ester protected intermediates instead of the methyl ester analogues. After activation of N-Boc-D-allo-isoleucine (VII) with carbonyl diimidazole, condensation with the lithium enolate of benzyl acetate yielded keto ester (LIV). Reduction of the keto group of (LIV), followed by silylation of the resultant alcohol (LV) and benzyl group hydrogenolysis led to the amino hydroxy acid derivative (XI)
| 【1】 Edge, A. (Diacrin, Inc.); Method for improving graft acceptance in a recipient by administration of a cytokine profile altering agent. WO 0051630 . |
| 中间体序号 | 中间体编号 | 品名 | CAS号 | 分子式 | 供应商 | 用于合成 |
|---|---|---|---|---|---|---|
| (VII) | 50775 | (2R,3S)-2-[(tert-butoxycarbonyl)amino]-3-methylpentanoic acid | C11H21NO4 | 详情 | 详情 | |
| (XI) | 50802 | (3S,4R,5S)-4-[(tert-butoxycarbonyl)amino]-3-[[tert-butyl(dimethyl)silyl]oxy]-5-methylheptanoic acid | C19H39NO5Si | 详情 | 详情 | |
| (LIV) | 62561 | benzyl (4R,5S)-4-[(tert-butoxycarbonyl)amino]-5-methyl-3-oxoheptanoate | C20H29NO5 | 详情 | 详情 | |
| (LV) | 62562 | benzyl (3S,4R,5S)-4-[(tert-butoxycarbonyl)amino]-3-hydroxy-5-methylheptanoate | C20H31NO5 | 详情 | 详情 |
合成路线4
该中间体在本合成路线中的序号：(XI)Similarly, (S)-2-hydroxy-3-methylbutyric acid (LV) was protected as the silyl ether (LVI) and then condensed with benzyl acetate, via activation with CDI, to afford keto ester (LVII). Subsequent methylation of (LVII) using iodomethane and NaH provided (XVI) as a diastereomeric mixture. The unstable keto acid (XVII), obtained in situ by catalytic hydrogenolysis of (XVI), was then coupled to the dipeptide ester (XV) to afford, after desilylation, the hydroxy keto amide (XIX). Esterification of alcohol (XIX) with the isostatine derivative (XI) as in Scheme 3, followed by acidic cleavage of the O-silyl and N-Boc protecting groups led to depsipeptide (XXI)
| 【1】 Edge, A. (Diacrin, Inc.); Method for improving graft acceptance in a recipient by administration of a cytokine profile altering agent. WO 0051630 . |
| 中间体序号 | 中间体编号 | 品名 | CAS号 | 分子式 | 供应商 | 用于合成 |
|---|---|---|---|---|---|---|
| (XI) | 50802 | (3S,4R,5S)-4-[(tert-butoxycarbonyl)amino]-3-[[tert-butyl(dimethyl)silyl]oxy]-5-methylheptanoic acid | C19H39NO5Si | 详情 | 详情 | |
| (XV) | 50792 | benzyl (2S)-1-[(2S)-2-amino-4-methylpentanoyl]-2-pyrrolidinecarboxylate | C18H26N2O3 | 详情 | 详情 | |
| (XVI) | 62563 | benzyl (4S)-4-{[tert-butyl(dimethyl)silyl]oxy}-2,5-dimethyl-3-oxohexanoate | C21H34O4Si | 详情 | 详情 | |
| (XVII) | 50791 | (2S,4S)-4-[[tert-butyl(dimethyl)silyl]oxy]-2,5-dimethyl-3-oxohexanoic acid | C14H28O4Si | 详情 | 详情 | |
| (XIX) | 62564 | benzyl (2S)-1-((2S)-2-{[(4S)-4-hydroxy-2,5-dimethyl-3-oxohexanoyl]amino}-4-methylpentanoyl)-2-pyrrolidinecarboxylate | C26H38N2O6 | 详情 | 详情 | |
| (XXI) | 62536 | benzyl (2S)-1-{(2S)-2-[((4S)-4-{[(3S,4R,5S)-4-amino-3-hydroxy-5-methylheptanoyl]oxy}-2,5-dimethyl-3-oxohexanoyl)amino]-4-methylpentanoyl}-2-pyrrolidinecarboxylate | C34H53N3O8 | 详情 | 详情 | |
| (LV) | 37829 | (2S)-2-hydroxy-3-methylbutyric acid | C5H10O3 | 详情 | 详情 | |
| (LVI) | 52726 | (2S)-2-{[tert-butyl(dimethyl)silyl]oxy}-3-methylbutanoic acid | C11H24O3Si | 详情 | 详情 | |
| (LVII) | 50790 | benzyl (4S)-4-[[tert-butyl(dimethyl)silyl]oxy]-5-methyl-3-oxohexanoate | C20H32O4Si | 详情 | 详情 |